Damora Therapeutics Inc (DMRA)

Damora Therapeutics Inc stock is traded at $21.86, with a volume of 793,811. It is down -4.71% in the last 24 hours and up +8.11% over the past month. Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.